Vaishali Pharma
Vaishali Pharma Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Vaishali Pharma Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Valuation
Profitability
Growth
Financial Health
Vaishali Pharma Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Vaishali Pharma Ltd, switchable between annual and quarterly views, consolidated or standalone.
Vaishali Pharma Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹93.67 Cr and reported EPS of ₹0.33.
| Period | 2026 |
|---|---|
| Revenue from Operations | 109 |
| Other Income | 4 |
| Total Income | 113 |
| Cost of Goods Sold (COGS) | 95 |
| Gross Profit | 14 |
| +Operating Expenses | 10 |
| EBITDA | 4 |
| +Non-Operating Expenses | 3 |
| Profit Before Tax (PBT) | 5 |
| +Tax Expense | 1 |
| Profit After Tax (PAT) | 4 |
| Earnings Per Share (EPS) | 0.32 |
| Diluted Shares Outstanding (Nos.) | 13 |
| +Additional Disclosures | 203 |
| Employee Cost % | 3 |
| Other Cost % | 6 |
| OPM % | 4 |
| Tax % | 25 |
| Gross Margin % | 0.00 |
| EBITDA Margin % | 0.00 |
| Interest Coverage Ratio | 0.00 |
| Additional Fields | 4 |
Vaishali Pharma segment analysis: revenue and profit mix.
Disclosed business segments at Vaishali Pharma with their share of revenue and profit, switchable between consolidated and standalone reporting.
Vaishali Pharma discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Vaishali Pharma Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Vaishali Pharma Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Vaishali Pharma Ltd's investment case rests on 9 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Latest quarter sales increased significantly by 31.40%.
Very low debt-to-equity ratio of 0.19 indicates financial stability.
Diversified product portfolio includes APIs, formulations, nutraceuticals, and veterinary.
Global market presence across Asia, Africa, America, and Middle East.
Achieved 10.51% positive revenue growth over the past five years.
What can break it.
Stock trades at an exceptionally high P/E ratio of 256.05.
Negative ROE -3.50% and OPM -1.33% reflect poor profitability.
Latest quarterly profit after tax declined significantly by -24.70%.
Low promoter shareholding at 26.3% suggests limited insider confidence.
Annual cash flow per share is negative, indicating liquidity concerns.
What would change my mind.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Vaishali Pharma Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Vaishali Pharma Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Vaishali Pharma Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Vaishali Pharma Ltd — derived from the live tape, not yesterday's close.
Vaishali Pharma Ltd last traded at ₹8.29 with an intraday range of ₹8.2–₹8.75 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹8.29| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 9.73 | +1.44 | +17.33% |
| R3 | 9.18 | +0.89 | +10.70% |
| R2 | 8.96 | +0.67 | +8.12% |
| R1 | 8.63 | +0.34 | +4.06% |
| PIVOT | 8.41 | 0.12 | 1.49% |
| CURRENT | 8.29 | — | — |
| S1 | 6.98 | -1.31 | -15.84% |
| S2 | 7.53 | -0.76 | -9.21% |
| S3 | 7.86 | -0.43 | -5.15% |
| S4 | 8.08 | -0.21 | -2.57% |
VAISHALI is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ~
Trading Below opening range, showing Bearishness
Vaishali Pharma Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Vaishali Pharma Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Vaishali Pharma Ltd stood at 67.5% of traded volume, against a 20-day average of 65.8%.
Vaishali Pharma announcements: results, concalls, ratings, M&A.
Filings Vaishali Pharma sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Vaishali Pharma files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 35 documents below.
Shareholders meeting
Vaishali Pharma Limited has informed the Exchange regarding Notice of Postal Ballot
Copy of Newspaper Publication
Vaishali Pharma Limited has informed the Exchange about Copy of Newspaper Publication
Outcome of Board Meeting
Vaishali Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on May 23, 2026.
Price movement
Significant movement in price has been observed in Vaishali Pharma Limited. The Exchange, in order to ensure that investors have latest relevant…
Price movement
Significant movement in price has been observed in Vaishali Pharma Limited. The Exchange, in order to ensure that investors have latest relevant…
Vaishali Pharma dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Vaishali Pharma has declared, sequenced by announce and record date.
Vaishali Pharma corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Vaishali Pharma Ltd: business, sector, key facts.
What Vaishali Pharma Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Vaishali Pharma Ltd operates in the Pharmaceuticals industry under the Health Care sector, listed as NSE: VAISHALI.
Vaishali Pharma Limited is an Indian pharmaceutical company with a global reach, primarily involved in the manufacturing and distribution of a wide range of pharmaceutical products. Their business model encompasses both active pharmaceutical ingredients (APIs) and finished formulations, catering to various therapeutic areas.
The company's API portfolio is extensive, covering a broad spectrum of therapeutic classes. This includes antibiotics, anti-ulcer medications, anti-inflammatory drugs, analgesics, antipyretics, anti-malarials, cardiac medications, anti-diabetics, anti-cold and anti-allergic drugs, anti-diarrheal, anti-protozoal and anti-parasitic agents, anti-virals, anti-epileptics, anti-asthmatics, anti-fungals, anti-platelet agents, skeletal muscle relaxants, and anti-helminthics. They also produce a variety of excipients, topical steroids, corticosteroids, and enzymes, crucial components in drug manufacturing.
In addition to APIs, Vaishali Pharma offers a diverse range of finished pharmaceutical formulations. These include antibiotics, anti-platelet agents, laxatives, anti-ulcer medications, anti-asthmatics, anti-malarials, anti-cold and anti-allergic medications, anti-virals, anti-psychotics, cardiac medications, anti-diabetics, anti-inflammatory and analgesic drugs, topical steroids and corticosteroids, anti-fungals, and vitamins. Beyond these core offerings, they also extend their product line to include veterinary products, nutraceuticals, oncology medications, herbal remedies, and surgical products.
Established in 1989 and headquartered in Mumbai, India, Vaishali Pharma Limited has built a substantial presence in the pharmaceutical industry, demonstrating a commitment to providing a comprehensive array of pharmaceutical solutions across various therapeutic categories and market segments. Their integrated approach, encompassing both API and formulation development and manufacturing, allows for greater control over product quality and supply chain efficiency.
Questions investors ask about Vaishali Pharma Ltd (VAISHALI).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Vaishali Pharma Ltd (VAISHALI)?
The current share price of Vaishali Pharma Ltd (VAISHALI) is ₹8.29. Today, the stock has declined by ₹0.51 (5.80%), trading in a range of ₹8.2 to ₹8.75. The stock opened at ₹8.61 with a trading volume of 4,19,175 shares.
02Is Vaishali Pharma Ltd stock a good investment for long-term?
Vaishali Pharma Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹93.67 crores, P/E ratio of 0.00, ROE of -4.70%, and ROCE of 4.93%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Vaishali Pharma Ltd stock?
The 52-week high price of Vaishali Pharma Ltd (VAISHALI) is ₹13.59, while the 52-week low is ₹4.75. Currently trading at ₹8.29, the stock is 40.0% away from its 52-week low and 39.0% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Vaishali Pharma Ltd stock at the current price?
Whether to buy Vaishali Pharma Ltd stock at ₹8.29 depends on multiple factors. The stock is currently trading with a P/E ratio of 0.00 and P/B ratio of 1.26. Today's performance shows a loss of 5.80%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Vaishali Pharma Ltd and when is the next dividend?
Vaishali Pharma Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹8.29, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Vaishali Pharma Ltd?
Vaishali Pharma Ltd's key financial metrics include: P/E Ratio: 0.00, P/B Ratio: 1.26, ROE: -4.70%, ROCE: 4.93%, Dividend Yield: 0.00%, EPS: ₹0.33, Book Value: ₹4.98, and Debt-to-Equity: 0.19. The company's market cap stands at ₹93.67 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Vaishali Pharma Ltd stock performing today in the market?
Vaishali Pharma Ltd stock opened at ₹8.61 and is currently trading at ₹8.29, showing a decline of ₹0.51 (5.80%). The intraday high is ₹8.75 and low is ₹8.2. The trading volume stands at 4,19,175 shares, indicating moderate market participation today.
08What is the P/E ratio of Vaishali Pharma Ltd and what does it indicate?
Vaishali Pharma Ltd has a Price-to-Earnings (P/E) ratio of 0.00, which means investors are willing to pay ₹0.00 for every ₹1 of earnings. With an EPS of ₹0.33, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Vaishali Pharma Ltd (VAISHALI) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- 3B Blackbio DX (3BBLACKBIO) Share PricePeer
- Abbott India (ABBOTINDIA) Share PricePeer
- Acutaas Chemicals (ACUTAAS) Share PricePeer
- AHCL (AHCL) Share PricePeer
- AMANTA (AMANTA) Share PricePeer
- Top Losers TodayScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy